Featuring an Industry Case Study from Glycotope Explaining the Benefits of using ambr® 15 Micro Bioreactors
Cambridge, UK – January 27, 2016: Sartorius Stedim Biotech (SSB) today announced that it will be presenting a new bioprocess webinar with Glycotope, a global leader in glyco-optimisation of biopharmaceuticals, on Wednesday, February 17th. Two live events (at 09.00 GMT and 16.00 GMT) will detail how Glycotope is using the ambr® 15 cell culture automated micro bioreactor system as a sedimentation-perfusion model to accelerate bioprocess development of protein-based therapeutics.
During the one-hour webinar, Dr Barney Zoro, ambr 15 Product Manager at SSB, will introduce ambr 15, the industry gold standard cell culture micro bioreactor. He will briefly describe the potential of the ambr 15 system to accelerate bioprocess development with industry data demonstrating the consistency and scalability of ambr 15 micro bioreactors when compared to benchtop and larger scale bioreactors.
Steffen Kreye, USP Development Scientist at Glycotope, will outline Glycotope’s use of the ambr 15 system as a micro-scale model for perfusion bioreactor cultures using Glycotope’s fully human, high yield production and glyco optimisation platform GlycoExpress (GEX) characterized by unmet reproducibility and scalability. The down-scale sedimentation-perfusion model system “SAM” achieves 99.9% cell retention for GEX and CHO cells.
Kreye will discuss how the ambr 15 ”SAM” cultures show excellent correlation for cell growth, metabolite and product quality profiles to 1L perfusion cultures with ATF™ or Centritech®. He will also detail how the ambr 15 “SAM” approach reproducibly predicts high quality attributes of GEX products at large scales and successfully predicts responses in VCD and titre to feed additives - not fully achievable with batch or chemostat culture.
To join the webinar and receive a recording to listen to on-demand, scientists should register at: http://www.tapbiosystems.com/ambr_webinar/ambr15Glycotopewebinar_Jan16.htm
Dr Barney Zoro, ambr 15 Product Manager, at SSB stated: "I am delighted to be hosting a webinar with Steffen Kreye, where he will discuss how the ambr 15 system is being used with a specialized cell line in perfusion culture as a micro-scale model to develop robust, high performance bioprocesses.”
Zoro concluded: “Scientists using or moving towards cell culture micro bioreactors or larger scale perfusion processes should register today for this exciting webinar to learn how using the ambr 15 technology can help to deliver faster and more cost-effective development of higher quality protein-based therapies.”
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”
Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.
About GlycoExpress (GEX™) from GLYCOTOPE
The GEX™ platform comprises a comprehensive portfolio of glyco-engineered human suspension cell lines, which allow for the production and optimisation of proteins with tailored and human glycosylation patterns (including optimised sialylation, galactosylation, fucosylation, branching and lack of non-human sugar structures). The perfusion system has evolved to a high yield production system (e.g. production levels of ADCC enhanced antibodies of 10-20 g/L bioreactor volume and up to 0.8 g/L per day; blood coagulation factor ~2 g/L) combined with an unmet reproducibility and quality, as well as full scalability. The GEX™ platform is approved by several regulatory authorities for clinical use (e.g. EMA, FDA) and is clinically validated. Based on its unique features the GlycoExpress™ platform is capable for the high yield production and optimisation of a variety of glycosylated biopharmaceuticals such as antibodies including IgG, IgM, and IgA, coagulation factors, cytokines, glycoprotein hormones and other difficult to express proteins.
Cambridge, UK – January 27, 2016: Sartorius Stedim Biotech (SSB) today announced that it will be presenting a new bioprocess webinar with Glycotope, a global leader in glyco-optimisation of biopharmaceuticals, on Wednesday, February 17th. Two live events (at 09.00 GMT and 16.00 GMT) will detail how Glycotope is using the ambr® 15 cell culture automated micro bioreactor system as a sedimentation-perfusion model to accelerate bioprocess development of protein-based therapeutics.
During the one-hour webinar, Dr Barney Zoro, ambr 15 Product Manager at SSB, will introduce ambr 15, the industry gold standard cell culture micro bioreactor. He will briefly describe the potential of the ambr 15 system to accelerate bioprocess development with industry data demonstrating the consistency and scalability of ambr 15 micro bioreactors when compared to benchtop and larger scale bioreactors.
Steffen Kreye, USP Development Scientist at Glycotope, will outline Glycotope’s use of the ambr 15 system as a micro-scale model for perfusion bioreactor cultures using Glycotope’s fully human, high yield production and glyco optimisation platform GlycoExpress (GEX) characterized by unmet reproducibility and scalability. The down-scale sedimentation-perfusion model system “SAM” achieves 99.9% cell retention for GEX and CHO cells.
Kreye will discuss how the ambr 15 ”SAM” cultures show excellent correlation for cell growth, metabolite and product quality profiles to 1L perfusion cultures with ATF™ or Centritech®. He will also detail how the ambr 15 “SAM” approach reproducibly predicts high quality attributes of GEX products at large scales and successfully predicts responses in VCD and titre to feed additives - not fully achievable with batch or chemostat culture.
To join the webinar and receive a recording to listen to on-demand, scientists should register at: http://www.tapbiosystems.com/ambr_webinar/ambr15Glycotopewebinar_Jan16.htm
Dr Barney Zoro, ambr 15 Product Manager, at SSB stated: "I am delighted to be hosting a webinar with Steffen Kreye, where he will discuss how the ambr 15 system is being used with a specialized cell line in perfusion culture as a micro-scale model to develop robust, high performance bioprocesses.”
Zoro concluded: “Scientists using or moving towards cell culture micro bioreactors or larger scale perfusion processes should register today for this exciting webinar to learn how using the ambr 15 technology can help to deliver faster and more cost-effective development of higher quality protein-based therapies.”
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”
Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.
About GlycoExpress (GEX™) from GLYCOTOPE
The GEX™ platform comprises a comprehensive portfolio of glyco-engineered human suspension cell lines, which allow for the production and optimisation of proteins with tailored and human glycosylation patterns (including optimised sialylation, galactosylation, fucosylation, branching and lack of non-human sugar structures). The perfusion system has evolved to a high yield production system (e.g. production levels of ADCC enhanced antibodies of 10-20 g/L bioreactor volume and up to 0.8 g/L per day; blood coagulation factor ~2 g/L) combined with an unmet reproducibility and quality, as well as full scalability. The GEX™ platform is approved by several regulatory authorities for clinical use (e.g. EMA, FDA) and is clinically validated. Based on its unique features the GlycoExpress™ platform is capable for the high yield production and optimisation of a variety of glycosylated biopharmaceuticals such as antibodies including IgG, IgM, and IgA, coagulation factors, cytokines, glycoprotein hormones and other difficult to express proteins.
